Compare Stocks: ANAB, KNSA, SRRK, and KOD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.53 -0.2%	$55.04	$19.65 ▼ $72.36	$1.45B	0.76	573,517 shs	441,119 shs
KNSA Kiniksa Pharmaceuticals International	$75.79 +0.8%	$77.30	$35.20 ▼ $82.94	$5.87B	0.04	564,645 shs	376,306 shs
KOD Kodiak Sciences	$94.45 -4.1%	$43.53	$10.94 ▼ $104.00	$6.19B	2.03	3.37 million shs	2.67 million shs
SRRK Scholar Rock	$46.81 +1.4%	$52.26	$27.07 ▼ $61.76	$5.62B	0.61	2.20 million shs	1.24 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.24%	-5.94%	-12.03%	-23.32%	+52.11%
KNSA Kiniksa Pharmaceuticals International	+0.82%	-0.16%	-5.12%	+16.57%	+94.67%
KOD Kodiak Sciences	+3.86%	+196.39%	+165.68%	+155.47%	+524.75%
SRRK Scholar Rock	-4.47%	-5.04%	-17.41%	-15.89%	+33.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$48.53 -0.2%	$55.04	$19.65 ▼ $72.36	$1.45B	0.76	573,517 shs	441,119 shs
KNSA Kiniksa Pharmaceuticals International	$75.79 +0.8%	$77.30	$35.20 ▼ $82.94	$5.87B	0.04	564,645 shs	376,306 shs
KOD Kodiak Sciences	$94.45 -4.1%	$43.53	$10.94 ▼ $104.00	$6.19B	2.03	3.37 million shs	2.67 million shs
SRRK Scholar Rock	$46.81 +1.4%	$52.26	$27.07 ▼ $61.76	$5.62B	0.61	2.20 million shs	1.24 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.24%	-5.94%	-12.03%	-23.32%	+52.11%
KNSA Kiniksa Pharmaceuticals International	+0.82%	-0.16%	-5.12%	+16.57%	+94.67%
KOD Kodiak Sciences	+3.86%	+196.39%	+165.68%	+155.47%	+524.75%
SRRK Scholar Rock	-4.47%	-5.04%	-17.41%	-15.89%	+33.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	60.28% Upside
KNSA Kiniksa Pharmaceuticals International	2.78	Moderate Buy	$93.14	22.90% Upside
KOD Kodiak Sciences	2.63	Moderate Buy	$100.43	6.33% Upside
SRRK Scholar Rock	2.94	Moderate Buy	$66.75	42.60% Upside

Current Analyst Ratings Breakdown

Latest ANAB, KNSA, SRRK, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$103.00
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/30/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$87.00
9/28/2026	KOD Kodiak Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$112.00
9/28/2026	KOD Kodiak Sciences	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$85.00 ➝ $145.00
9/28/2026	KOD Kodiak Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$80.00 ➝ $120.00
9/28/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $96.00
9/24/2026	SRRK Scholar Rock	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$76.00 ➝ $77.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/24/2026	KOD Kodiak Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$232.39M	6.24	N/A	N/A	$1.34 per share	36.22
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.73	$0.80 per share	94.76	$7.44 per share	10.19
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	9.04	40.78	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	78.13	36.61	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest ANAB, KNSA, SRRK, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.39	N/A	N/A	N/A	$259.65 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/13/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
KOD Kodiak Sciences	N/A	2.49	2.49
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
KOD Kodiak Sciences	89.06%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
KNSA Kiniksa Pharmaceuticals International	51.98%
KOD Kodiak Sciences	44.40%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable

ANAB, KNSA, SRRK, and KOD Headlines

Recent News About These Companies

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

September 30 at 9:56 AM | prnewswire.com

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

September 28, 2026 | finance.yahoo.com

Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says

September 25, 2026 | finance.yahoo.com

Scholar Rock (NASDAQ:SRRK) Trading 6% Higher After Analyst Upgrade

September 24, 2026 | americanbankingnews.com

How Scholar Rock Holding Corporation (SRRK) Affects Rotational Strategy Timing

September 23, 2026 | news.stocktradersdaily.comN

Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade

September 22, 2026 | marketbeat.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2026

September 22, 2026 | biospace.comB

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 21, 2026 | marketbeat.com

Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK

September 21, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Receives a Buy from Piper Sandler

September 17, 2026 | theglobeandmail.com

Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group

September 17, 2026 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Scholar Rock

September 17, 2026 | marketbeat.com

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

September 16, 2026 | insidermonkey.com

Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions

September 15, 2026 | finance.yahoo.com

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

September 15, 2026 | finance.yahoo.com

Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

September 15, 2026 | seekingalpha.com

Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

September 15, 2026 | msn.com

Scholar Rock (NASDAQ:SRRK) Shares Down 7.1% - Here's What Happened

September 15, 2026 | marketbeat.com

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

September 15, 2026 | benzinga.com

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

September 14, 2026 | finance.yahoo.com

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

September 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANAB, KNSA, SRRK, and KOD Company Descriptions

AnaptysBio NASDAQ:ANAB

$48.53 -0.10 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$48.58 +0.05 (+0.09%)

As of 07:30 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$75.79 +0.57 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$75.69 -0.10 (-0.13%)

As of 07:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Kodiak Sciences NASDAQ:KOD

$94.45 -4.01 (-4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$94.29 -0.16 (-0.17%)

As of 07:59 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Scholar Rock NASDAQ:SRRK

$46.81 +0.65 (+1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$47.05 +0.24 (+0.51%)

As of 07:30 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, KNSA, SRRK, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, KNSA, SRRK, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, KNSA, SRRK, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANAB, KNSA, SRRK, and KOD Company Descriptions

AnaptysBio NASDAQ:ANAB

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Kodiak Sciences NASDAQ:KOD

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANAB, KNSA, SRRK, and KOD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANAB, KNSA, SRRK, and KOD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANAB, KNSA, SRRK, and KOD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANAB, KNSA, SRRK, and KOD Company Descriptions

AnaptysBio NASDAQ:ANAB

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Kodiak Sciences NASDAQ:KOD

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools